Escape of human immunodeficiency virus type 1 from broadly neutralizing antibodies is not associated with a reduction of viral replicative capacity in vitro. (Q45406304)

From Wikidata

Jump to navigation Jump to search

scientific article published on 13 March 2007

Language	Label	Description	Also known as
English	Escape of human immunodeficiency virus type 1 from broadly neutralizing antibodies is not associated with a reduction of viral replicative capacity in vitro.	scientific article published on 13 March 2007

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17355886%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Escape of human immunodeficiency virus type 1 from broadly neutralizing antibodies is not associated with a reduction of viral replicative capacity in vitro (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17355886%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

1 reference

based on heuristic

inferred from title

Evelien M. Bunnik

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17355886%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Hanneke Schuitemaker

6

object named as

Hanneke Schuitemaker

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17355886%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

author name string

Esther D Quakkelaar

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17355886%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Floris P J van Alphen

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17355886%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Brigitte D M Boeser-Nunnink

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17355886%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Ad C van Nuenen

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17355886%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

language of work or name

0 references

publication date

13 March 2007

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17355886%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

363

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17355886%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17355886%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

447-453

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17355886%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.02.011

7 January 2021

Increased sensitivity to CD4 binding site-directed neutralization following in vitro propagation on primary lymphocytes of a neutralization-resistant human immunodeficiency virus IIIB strain isolated from an accidentally infected laboratory worker

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.02.011

7 January 2021

Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.02.011

7 January 2021

In vitro replication kinetics of human immunodeficiency virus type 1 (HIV-1) variants in relation to virus load in long-term survivors of HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.02.011

7 January 2021

Neutralization escape in human immunodeficiency virus type 1-infected long-term nonprogressors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.02.011

7 January 2021

Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.02.011

7 January 2021

Antibody domain exchange is an immunological solution to carbohydrate cluster recognition

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.02.011

7 January 2021

Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.02.011

7 January 2021

Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.02.011

7 January 2021

Characterization of human immunodeficiency virus type 1 (HIV-1) envelope variation and neutralizing antibody responses during transmission of HIV-1 subtype B.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.02.011

7 January 2021

Increased In Vitro Cytopathicity of CC Chemokine Receptor 5–Restricted Human Immunodeficiency Virus Type 1 Primary Isolates Correlates with a Progressive Clinical Course of Infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.02.011

7 January 2021

Failure of zidovudine prophylaxis after accidental exposure to HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.02.011

7 January 2021

Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.02.011

7 January 2021

A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.02.011

7 January 2021

Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.02.011

7 January 2021

Viremia control despite escape from a rapid and potent autologous neutralizing antibody response after therapy cessation in an HIV-1-infected individual

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.02.011

7 January 2021

Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.02.011

7 January 2021

Neutralizing Antibody Responses to Human Immunodeficiency Virus Type 1 in Primary Infection and Long‐Term‐Nonprogressive Infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.02.011

7 January 2021

gp120: Biologic aspects of structural features

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.02.011

7 January 2021

Selection of human immunodeficiency virus type 1 R5 variants with augmented replicative capacity and reduced sensitivity to entry inhibitors during severe immunodeficiency.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.02.011

7 January 2021

Rapid evolution of the neutralizing antibody response to HIV type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.02.011

7 January 2021

The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.02.011

7 January 2021

The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.02.011

7 January 2021

Detection and subtyping of HIV-1 isolates with a panel of characterized monoclonal antibodies to HIV p24gag

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.02.011

7 January 2021

Emerging resistance to nonnucleoside reverse transcriptase inhibitors: a warning and a challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.02.011

7 January 2021

Neutralization of multiple HIV-1 isolates from a single subject by autologous sequential sera

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.02.011

7 January 2021

Changes in human immunodeficiency virus type 1 fitness and genetic diversity during disease progression

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.02.011

7 January 2021

Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.02.011

7 January 2021

Transmission of zidovudine-resistant human immunodeficiency virus type 1 variants following deliberate injection of blood from a patient with AIDS: characteristics and natural history of the virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.02.011

7 January 2021

Antibody neutralization and escape by HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.02.011

7 January 2021

Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.02.011

7 January 2021

Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.02.011

7 January 2021

Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.02.011

7 January 2021

based on heuristic

inferred from DOI database lookup

Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.02.011

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45406304&oldid=2160634899"